

**Staphylococcus aureus - NRS79**  
Other designations ( IL )

Demographic Information:			
Country/State:	United States / Illinois	Date of Isolation:	04/27/ <del>2004</del> 1999
Patient Age:	63 Year(s)	Gender:	Female
Patient Location:	Inpatient	Patient Service:	Medicine
Culture Source:			
Literature Citation:	Boyle-Vavra, S., et al. 2001. Journal of Antimicrobial Chemotherapy 48(5):617-625. MMWR. January 7,2000. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. CDC 48(51):1165-1167.		
Donor Reported MIC Results (ug/ml)	Vancomycin = 8	Teicoplanin = 16	
Comment:	N/A		
Repositories:	Glycopeptide Intermediate Staphylococci		

NARSA Antimicrobial Susceptibility Data for Glycopeptides

Drug	Broth Microdilution		<sup>a</sup> Conventional Etest 0.5 McFarland Std		<sup>b</sup> Modified Etest 2 McFarland Std		BHI Agar Screen	Disk Diffusion	
	MIC <del>ug/mL</del> P=not	CLSI Interpretn	MIC, ug/ml	CLSI Interprtn	MIC, ug/ml	CLSI Interprtn		Zone diam. (mm)	CLSI Interprtn
Vancomycin:	= 2	S	= 3	S	= 8	I	IC(48)	17	S
Teicoplanin:	= 4	S	= 6	S	= 16	I		15	S

S = Susceptible; R = Resistant; NS = Not Susceptible; I =Intermediate; N/A = Not Available P= Pending results

NARSA Antimicrobial Profile for Other Antimicrobial Agents			Molecular Characterization Data	
Drug	MIC <del>ug/mL</del> (ug/ml)	CLSI Interpretn	PCR	Result
Ciprofloxacin	> 16	R	<i>vanA</i>	NEGATIVE
Clindamycin	> 4	R	<i>vanB</i>	NEGATIVE
Daptomycin	= 2	N/A	<i>vanC1</i>	NEGATIVE
Erythromycin	> 8	R	<i>vanC2</i>	NEGATIVE
Gentamicin	= 2	S	<i>vanD</i>	NEGATIVE
Linezolid	= 2	S	<i>vanE</i>	NEGATIVE
Oxacillin	> 16	R	<i>mecA</i>	POSITIVE
Penicillin	> 2	R		
Quinupristin/dalfopristin	= 0.5	S		
Trimeth/sulfa	<= 0.25/4.75	S		

Genotype Data	
Genotype	Result
eGenomic <i>spa</i> type	2
eGenomic <i>spa</i> repeats	TJMBMDMGMK
Ridom <i>spa</i> type	002
SCC <i>mec</i> type	II
Clonal Complex (CC)	5
Sequence Type (ST)	231
<a href="#">Genotype Data file</a>	